TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04571528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment VIRTUAL FIBROWALK
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU + Physiotherapy part of VIRTUAL FIBROWALK
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients: - Pain neuroscience education (30 min.) - Physical exercise(30 min.) - Treatment as Usual (TAU). Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study: NCT00838149

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Study: NCT01336361

Intervention type: OTHER
Intervention: Survey
Description: A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
Study: NCT02607748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET and coronary CTA imaging
Study: NCT02939131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm
Description: Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
Study: NCT03163602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Access flap and debridement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test group
Description: Regenerative treatment
Study: NCT02185976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cartoon
Description: 5 different cartoons which will be recorded on a tablet PC.
Study: NCT03995719

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative education
Description: 65 patients were instructed to a preoperative stoma-education program

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative education
Description: 65 patients were instructed to a preoperative stoma-education program
Study: NCT03257709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acetabular labral repair
Description: Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acetabular labral resection
Description: The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
Study: NCT02122783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADR™ brace resistance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADR™ brace resistance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional brace resistance (using hard stops)
Description: Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional brace resistance (using hard stops)
Description: Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
Study: NCT02783079

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Study: NCT04570059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on textured food introduction between 8 and 15 months
Description: Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling on textured food introduction between 8 and 15 months
Description: Intervention program : Advice and tips on the why and how introducing textured food during complementary feeding are grouped in a booklet and provided to participants. Monthly counselling via phone call by a dietician (at 9, 10, 11,12, 13, 14 months) and two baskets containing food preparation utensils and commercial textured foods provided at 8 and 12 months.~Usual care : reflects the standard information provided within French national guidelines (PNNS). Two phone calls at 9 and 13 months. If questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS. Two gift boxes containing presents for the child of same financial value as those provided to intervention group, provided at 8 and 12 months.
Study: NCT04440605

Intervention type: PROCEDURE
Intervention: Preoperative staging--D2 gastrectomy--Postoperative staging
Description: Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy

Intervention type: PROCEDURE
Intervention: Preoperative staging--D2 gastrectomy--Postoperative staging
Description: Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
Study: NCT03995719

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative education
Description: 73 patients, receiving the same information in postoperative period.

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative education
Description: 73 patients, receiving the same information in postoperative period.
Study: NCT01286584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
Study: NCT04440605

Intervention type: PROCEDURE
Intervention: Preoperative staging--D2 gastrectomy--Postoperative staging
Description: Preoperative TNM staging under CT scan plus endoscopy endoscopic biopsy, and postoperative staging after D2 gastrectomy
Study: NCT00338182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152 part A
Description: 48-hour continuous intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152 part B
Description: 2-hour intravenous infusion
Study: NCT01873521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Study: NCT04286997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRAIL population
Description: each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
Study: NCT00840827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 10mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: CSA 250mg orally twice daily
Study: NCT02319902

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard cold carbon dioxide gas
Description: Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated humidified carbon dioxide gas
Description: Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
Study: NCT04286997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GRAIL population
Description: each subjects included in the intervention group will receive 20 GRAIL sessions, aimed to the walking pattern improvement, associated with 20 traditional physiotherapy sessions, aimed to the stabilization of the trained competences
Study: NCT00957125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
Study: NCT01705067

Intervention type: DEVICE
Intervention: TKA with Journey II BCS Total Knee System
Description: TKA with Journey II BCS Total Knee System
Study: NCT00653432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monovisc®
Description: Intra-articular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% Sterile Saline
Study: NCT00005862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study: NCT03804671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 mixed with [C-14] BI 730357 BS
Description: Intravenous dose
Study: NCT03742778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivizing reflection
Description: Participants receive bonus incentives for reflecting on their workouts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentivizing exercise
Description: Participants receive bonus incentives for exercising
Study: NCT00891514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
Study: NCT02408692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ECx1
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ECx1
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ECx2
Description: At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
Study: NCT00838149

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine
Description: Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Study: NCT05434884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal veneer restorations
Description: occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars
Study: NCT00838149

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein
Description: Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
Study: NCT02984943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: 30 treatments of Hyperbaric Oxygen.
Study: NCT02540889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory comprehension therapy.
Description: 100 hours of Auditory comprehension therapy embedded within a computer game.
Study: NCT03229174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.

Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
Study: NCT05434884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endocrown restorations
Description: endocrown restorations
Study: NCT03268356

Intervention type: DEVICE
Group type: OTHER
Intervention: AGN1 Femoral Local Osteo-Enhancement Procedure Kit
Description: A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
Study: NCT03229174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (sugar pill)
Study: NCT02280122

Intervention type: OTHER
Intervention: no intervention provided
Description: No Intervention was rendered but the aMMP-8 test was made
Study: NCT00631878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
Study: NCT02402725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: (1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
Study: NCT03529071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKD-Question Prompt Sheet
Description: The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
Study: NCT00631878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
Study: NCT00088556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLK286
Description: Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 mg/mL/min Once every 3 weeks
Study: NCT00631878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pagibaximab (formerly BSYX-A110)
Description: Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
Study: NCT00088556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m² Once every 3 weeks
Study: NCT05306821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive electronic tool in the electronic medical chart
Description: Use of a comprehensive electronic tool in the electronic medical chart to help the stratification of risk of VTE and the subsequent prescription of an adequate thromboprophylaxis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educative sessions
Description: Educative sessions on thromboprophylaxis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educative sessions
Description: Educative sessions on thromboprophylaxis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pocket card
Description: Pocket card (guide for thromboprophylaxis)
Study: NCT02958683

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
Study: NCT01583478

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
Study: NCT02958683

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
Study: NCT02958683

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect

Intervention type: OTHER
Intervention: Chest wall motion analysis
Description: Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
Study: NCT01246154

Intervention type: OTHER
Intervention: EXERCISE TRAINING
Description: EXERCISE TRAINING
Study: NCT01565343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi)
Study: NCT01583478

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
Study: NCT03823391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-3373
Description: ABBV-3373 is administered as intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-3373
Description: Placebo for ABBV-3373 is administered as IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab is administered as subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab is administered as subcutaneous (SC) injection